ARS Pharmaceuticals (SPRY) Expected to Post Quarterly Earnings on Thursday

ARS Pharmaceuticals (NASDAQ:SPRY) is projected to release its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect ARS Pharmaceuticals to announce earnings of ($0.4765) per share and revenue of $31.3320 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its earnings results on Friday, May 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.08). The firm had revenue of $22.68 million during the quarter, compared to analyst estimates of $22.20 million. ARS Pharmaceuticals had a negative net margin of 200.00% and a negative return on equity of 153.61%. On average, analysts expect ARS Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ARS Pharmaceuticals Stock Performance

Shares of SPRY opened at $5.91 on Tuesday. The company has a market capitalization of $586.86 million, a PE ratio of -2.94 and a beta of 0.98. The company has a debt-to-equity ratio of 2.79, a current ratio of 4.94 and a quick ratio of 4.77. ARS Pharmaceuticals has a one year low of $4.91 and a one year high of $17.53. The company’s fifty day moving average price is $7.81 and its 200 day moving average price is $8.42.

Insider Buying and Selling at ARS Pharmaceuticals

In other news, insider Alexander A. Fitzpatrick sold 3,355 shares of the business’s stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $10.00, for a total transaction of $33,550.00. Following the transaction, the insider owned 90,910 shares in the company, valued at approximately $909,100. The trade was a 3.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Karas sold 25,000 shares of the company’s stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. Following the transaction, the insider directly owned 12,176 shares of the company’s stock, valued at $121,760. This represents a 67.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 33.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ARS Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Osterweis Capital Management Inc. bought a new stake in shares of ARS Pharmaceuticals in the 4th quarter worth approximately $65,000. Russell Investments Group Ltd. increased its position in shares of ARS Pharmaceuticals by 197.5% during the third quarter. Russell Investments Group Ltd. now owns 6,668 shares of the company’s stock valued at $67,000 after purchasing an additional 4,427 shares during the period. Quantbot Technologies LP bought a new stake in shares of ARS Pharmaceuticals during the third quarter valued at approximately $82,000. Osaic Holdings Inc. raised its stake in shares of ARS Pharmaceuticals by 52.8% in the second quarter. Osaic Holdings Inc. now owns 5,215 shares of the company’s stock valued at $91,000 after purchasing an additional 1,803 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its stake in shares of ARS Pharmaceuticals by 58.3% in the second quarter. BNP Paribas Financial Markets now owns 6,097 shares of the company’s stock valued at $106,000 after purchasing an additional 2,245 shares in the last quarter. 68.16% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

SPRY has been the topic of several research analyst reports. Weiss Ratings raised ARS Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 1st. Leerink Partners cut their price objective on ARS Pharmaceuticals from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Thursday, June 25th. Wall Street Zen upgraded ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Cantor Fitzgerald raised their target price on ARS Pharmaceuticals from $12.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 28th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $28.20.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.